The stock of Minerva Neurosciences Inc (NASDAQ:NERV) is a huge mover today! About 231,497 shares traded hands. Minerva Neurosciences Inc (NASDAQ:NERV) has risen 162.50% since March 7, 2016 and is uptrending. It has outperformed by 154.91% the S&P500.
The move comes after 9 months positive chart setup for the $490.66M company. It was reported on Oct, 10 by Barchart.com. We have $33.37 PT which if reached, will make NASDAQ:NERV worth $657.48 million more.
Analysts await Minerva Neurosciences Inc (NASDAQ:NERV) to report earnings on November, 3. They expect $-0.23 EPS, up 4.17% or $0.01 from last year’s $-0.24 per share. After $-0.18 actual EPS reported by Minerva Neurosciences Inc for the previous quarter, Wall Street now forecasts 27.78% negative EPS growth.
Minerva Neurosciences Inc (NASDAQ:NERV) Ratings Coverage
Out of 2 analysts covering Minerva Neurosciences (NASDAQ:NERV), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Minerva Neurosciences has been the topic of 3 analyst reports since March 9, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating by Jefferies given on Thursday, May 12. The company was maintained on Wednesday, March 9 by JMP Securities. Jefferies maintained Minerva Neurosciences Inc (NASDAQ:NERV) on Friday, May 27 with “Buy” rating.
According to Zacks Investment Research, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company’s pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States.”
More important recent Minerva Neurosciences Inc (NASDAQ:NERV) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on June 27, 2014, also Quotes.Wsj.com published article titled: “News Minerva Neurosciences Inc.NERV”, Marketwatch.com published: “Minerva Neurosciences’ stock more than triples on heavy volume after drug …” on May 26, 2016. More interesting news about Minerva Neurosciences Inc (NASDAQ:NERV) was released by: 247Wallst.com and their article: “Why Minerva’s Incredible Move May Be Justified” with publication date: May 27, 2016.
NERV Company Profile
Minerva Neurosciences, Inc., incorporated on April 23, 2007, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.